Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.55 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24536222 | 0.83 | SIGMAR1 (0.46) | SIGMAR1OPRM1MC4RKMT2AMEN1 | |
| SCHEMBL29080045 | 0.83 | SIGMAR1 (0.46) | SIGMAR1OPRM1MC4RKMT2AMEN1 | |
| SCHEMBL4772258 | 0.77 | SIGMAR1 (0.61) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL8825553 | 0.76 | SIGMAR1 (0.46) | SIGMAR1HRH3OPRM1MC4RDRD4 | |
| SCHEMBL2514685 | 0.76 | HRH3 (0.52) | SIGMAR1HRH3OPRM1KMT2AMEN1 | |
| SCHEMBL2257602 | 0.76 | SIGMAR1 (0.59) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL27323536 | 0.76 | SIGMAR1 (0.59) | SIGMAR1HRH3MC4RDRD4LMNA | |
| Water SCHEMBL8695926 | 0.75 | SIGMAR1 (0.95) | SIGMAR1MC4RDRD4LMNAPOLB | |
| SCHEMBL2452523 | 0.75 | SIGMAR1 (0.57) | SIGMAR1HRH3MC4RDRD4LMNA | |
| SCHEMBL8380136 | 0.75 | SIGMAR1 (0.57) | SIGMAR1HRH3MC4RDRD4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111072551-A | Method for preparing piperidine amine by catalytic hydrogenation one-step method | 上海睿瓦科技有限公司 | 2020-04-28 | — | — | CN | claimed |
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2025-01-30 | — | — | US | disclosed |
| EP-4415706-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-08-21 | — | — | EP | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-111072551-A | Method for preparing piperidine amine by catalytic hydrogenation one-step method | 上海睿瓦科技有限公司 | 2020-04-28 | — | — | CN | disclosed |
| CN-108349936-A | It is used to treat N- [2- (1- benzyl piepridine -4- bases) ethyl] -4- (pyrazine -2- bases)-piperazine -1- carboxamides derivatives and related compound of neurological disorder as muscarinic receptor 4 (M4) antagonist | 纽罗克里生物科学有限公司 | 2018-07-31 | — | — | CN | disclosed |
| EP-2727916-A1 | Neuroprotective multi-target directed drugs | Universitat Autònoma de Barcelona (ES) | 2014-05-07 | — | — | EP | disclosed |
| EP-2727916-A1 | Neuroprotective multi-target directed drugs | Universitat Autònoma de Barcelona (ES) | 2014-05-07 | — | — | EP | disclosed |
| US-8629277-B2 | Styrenyl 1,2,4-oxadiazole compounds | Piramal Enterprises Limited (IN) | 2014-01-14 | — | — | US | disclosed |
| CN-103108867-A | Oxadiazole compounds, their preparation and use | PIRAMAL LIFE SCIENCES LTD | 2013-05-15 | — | — | CN | disclosed |
| WO-2011104680-A1 | OXADIAZOLE COMPOUNDS, THEIR PREPARATION AND USE | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-09-01 | — | — | WO | disclosed |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| US-7498323-B2 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICALS CO., LTD. (JP) | 2009-03-03 | — | — | US | disclosed |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-12 | — | — | US | disclosed |
| EP-1619193-A1 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-25 | — | — | EP | disclosed |
| EP-1430898-A1 | RECEPTOR ANTAGONIST | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-23 | — | — | EP | disclosed |
| US-20040110826-A1 | Receptor Antagonists | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| US-20040092737-A1 | Benzopiperidine derivatives | EISAI CO., LTD. | 2004-05-13 | — | — | US | disclosed |
| US-6518423-B1 | These compounds are useful as drugs efficacious in the prevention and treatment of these various inflammatory diseases and immunologic diseases, such as rheumatoid arthritis, atopic dermatitis, psoriasis, asthma, and | EISAI CO., LTD. (JP) | 2003-02-11 | — | — | US | disclosed |
| EP-0934941-A1 | BENZOPIPERIDINE DERIVATIVES | Eisai Co., Ltd. (JP) | 1999-08-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034170-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | SIGMAR1 3740/4885HRH3 4370/4885OPRM1 3075/4885 |
| US-20040092737-A1 | Benzopiperidine derivatives | HLA-DRB1, HRH1, HRH2 | SIGMAR1 1579/4885HRH3 12/4885OPRM1 1879/4885 |
| US-20100261641-A1 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF | CCR1, CCR7, CCR3 | SIGMAR1 225/4885HRH3 61/4885OPRM1 436/4885 |
| US-20060229301-A1 | Spiro-piperidine compounds and medicinal use thereof | CCR1, CCR7, CCR3 | SIGMAR1 225/4885HRH3 61/4885OPRM1 436/4885 |
| US-20040110826-A1 | Receptor Antagonists | ADRA2C, OPRL1, ADRB1 | SIGMAR1 80/4885HRH3 216/4885OPRM1 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.